TY - JOUR T1 - Trans-ethnic genome-wide meta-analysis of 35,732 cases and 34,424 controls identifies novel genomic cross-ancestry loci contributing to lung cancer susceptibility JF - medRxiv DO - 10.1101/2020.10.06.20207753 SP - 2020.10.06.20207753 AU - Jinyoung Byun AU - Younghun Han AU - Yafang Li AU - Jun Xia AU - Xiangjun Xiao AU - Ryan Sun AU - Kyle M. Walsh AU - Ivan Gorlov AU - Olga Gorlova AU - Wen Zhou AU - Rowland W Pettit AU - Zhuoyi Song AU - Susan M Rosenberg AU - Dakai Zhu AU - John K. Wiencke AU - Demetrius Albanes AU - Stephan Lam AU - Adonina Tardon AU - Chu Chen AU - Gary Goodman AU - Stig Bojeson AU - Hermann Brenner AU - Maria Teresa Landi AU - Mattias Johansson AU - Thomas Mulley AU - Angela Risch AU - H-Erich Wichmann AU - Heike Bickeböller AU - David C. Christiani AU - Gad Rennert AU - Susanne Arnold AU - John K. Field AU - Sanjay Shete AU - Loic LeMarchand AU - Ole Melander AU - Hans Brunnstrom AU - Geoffrey Liu AU - Angeline S. Andrew AU - Lambertius A. Kiemeney AU - Hongbing Shen AU - Shan Zienolddiny AU - Kjell Grankvist AU - Mikael Johansson AU - Neil Caporaso AU - Angela Cox AU - Yun-Chul Hong AU - Jian-Min Yuan AU - Philip Lazarus AU - Matthew B. Schabath AU - Melinda C. Aldrich AU - Apla Patel AU - Qing Lan AU - Nat Rothman AU - Fiona Taylor AU - Margaret Spitz AU - Paul Brennan AU - Xihong Lin AU - James McKay AU - Rayjean J. Hung AU - Christopher I. Amos AU - INTEGRAL Consortium Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/07/2020.10.06.20207753.abstract N2 - Lung cancer is the leading cause of cancer death worldwide. Genome-wide association studies have revealed genetic risk factors, highlighting the role of smoking, family history, telomere regulation, and DNA damage-repair in lung cancer etiology. Many studies have focused on a single ethnic group to avoid confounding from variability in allele frequencies across populations; however, comprehensive multi-ethnic analyses may identify variants that are more likely to be causal. This large-scale, multi- ethnic meta-analyses identified 28 novel risk loci achieving genome-wide significance. Leading candidates were further studied using single-cell methods for evaluating DNA-damage. DNA-damage promoting activities were confirmed for selected genes by knockdown genes and overexpression studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOur study was supported by the National Institutes of Health (NIH) for Integrative Analysis of Lung Cancer Etiology and Risk (U19CA203654) and Cancer Prevention Research Interest of Texas (CPRIT) award (RR170048). Functional Studies for this research was partially supported by NIH grants (R01CA250905 and DP1-AG072751). The Resource for the Study of Lung Cancer Epidemiology in North Trent (ReSoLuCENT) study was funded by the Sheffield Hospitals Charity, Sheffield Experimental Cancer Medicine Centre and Weston Park Hospital Cancer Charity. FT was supported by a clinical PhD fellowship funded by the Yorkshire Cancer Research/Cancer Research UK Sheffield Cancer Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available at the database of Genotypes and Phenotypes (dbGaP). The access numbers are phs001273.v3.p2 for OncoArray study, phs000876.v2.p1 for Affymetrix study, phs000716.v1.p1 for FLCCA study, phs001210.v1.p1 for NCI study, and phs000629.v1.p1 for GELCC study. Other data that support the findings of this study are available from the corresponding author upon request and are also reported as summary data in phs001273.v3.p2 ER -